123 related articles for article (PubMed ID: 24013745)
1. IL-17 mediates resistance to anti-VEGF therapy.
Maniati E; Hagemann T
Nat Med; 2013 Sep; 19(9):1092-4. PubMed ID: 24013745
[TBL] [Abstract][Full Text] [Related]
2. Adaptive resistance of tumor cells to anti-vascular endothelial growth factor therapy: A reversible phenomenon.
Wang Z; Wang M; Guo J; Lu Y; Wei P
Cytokine; 2024 Aug; 180():156674. PubMed ID: 38852491
[TBL] [Abstract][Full Text] [Related]
3. Autophagy as a mechanism for anti-angiogenic therapy resistance.
Chandra A; Rick J; Yagnik G; Aghi MK
Semin Cancer Biol; 2020 Nov; 66():75-88. PubMed ID: 31472232
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
Pan J; Jin P; Yan J; Kabelitz D
Cancer Immunol Immunother; 2008 Aug; 57(8):1105-14. PubMed ID: 18214475
[TBL] [Abstract][Full Text] [Related]
5. A spatial model of tumor-host interaction: application of chemotherapy.
Hinow P; Gerlee P; McCawley LJ; Quaranta V; Ciobanu M; Wang S; Graham JM; Ayati BP; Claridge J; Swanson KR; Loveless M; Anderson AR
Math Biosci Eng; 2009 Jul; 6(3):521-46. PubMed ID: 19566124
[TBL] [Abstract][Full Text] [Related]
6. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis.
Yang B; Kang H; Fung A; Zhao H; Wang T; Ma D
Mediators Inflamm; 2014; 2014():623759. PubMed ID: 25110397
[TBL] [Abstract][Full Text] [Related]
7. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
Wong PP; Demircioglu F; Ghazaly E; Alrawashdeh W; Stratford MR; Scudamore CL; Cereser B; Crnogorac-Jurcevic T; McDonald S; Elia G; Hagemann T; Kocher HM; Hodivala-Dilke KM
Cancer Cell; 2015 Jan; 27(1):123-37. PubMed ID: 25584895
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
Liu S; Sun Q; Ren X
J Hematol Oncol; 2023 Apr; 16(1):38. PubMed ID: 37055849
[TBL] [Abstract][Full Text] [Related]
9. Current status and future of anti-angiogenic drugs in lung cancer.
Yan X; Zhao Z; Tang H
Clin Exp Med; 2023 Oct; 23(6):2009-2023. PubMed ID: 36920592
[TBL] [Abstract][Full Text] [Related]
10. IL-17A Enhances Retinal Neovascularization.
Taylor BE; Lee CA; Zapadka TE; Zhou AY; Barber KG; Taylor ZRR; Howell SJ; Taylor PR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675261
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL17A Halts the Onset of Diabetic Retinopathy in Type I and II Diabetic Mice.
Zhou AY; Taylor BE; Barber KG; Lee CA; Taylor ZRR; Howell SJ; Taylor PR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674854
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 During Unfavorable Peritoneal Tissue Remodeling in Patients Receiving Peritoneal Dialysis as Renal Replacement Therapy.
Catar RA; Bartosova M; Kawka E; Chen L; Marinovic I; Zhang C; Zhao H; Wu D; Zickler D; Stadnik H; Karczewski M; Kamhieh-Milz J; Jörres A; Moll G; Schmitt CP; Witowski J
Front Immunol; 2022; 13():821681. PubMed ID: 35185912
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
Gonda K; Horita S; Maejima Y; Takenoshita S; Shimomura K
Sci Prog; 2021; 104(3):368504211039590. PubMed ID: 34559590
[TBL] [Abstract][Full Text] [Related]
14. Retinal Inflammation, Oxidative Stress, and Vascular Impairment Is Ablated in Diabetic Mice Receiving XMD8-92 Treatment.
Howell SJ; Lee CA; Batoki JC; Zapadka TE; Lindstrom SI; Taylor BE; Taylor PR
Front Pharmacol; 2021; 12():732630. PubMed ID: 34456740
[TBL] [Abstract][Full Text] [Related]
15. RORγt Inhibitor-SR1001 Halts Retinal Inflammation, Capillary Degeneration, and the Progression of Diabetic Retinopathy.
Zapadka TE; Lindstrom SI; Taylor BE; Lee CA; Tang J; Taylor ZRR; Howell SJ; Taylor PR
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429598
[TBL] [Abstract][Full Text] [Related]
16. Adipocyte and lipid metabolism in cancer drug resistance.
Cao Y
J Clin Invest; 2019 Jul; 129(8):3006-3017. PubMed ID: 31264969
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.
Jabeen S; Zucknick M; Nome M; Dannenfelser R; Fleischer T; Kumar S; Lüders T; von der Lippe Gythfeldt H; Troyanskaya O; Kyte JA; Børresen-Dale AL; Naume B; Tekpli X; Engebraaten O; Kristensen V
Oncoimmunology; 2018; 7(11):e1457598. PubMed ID: 30377556
[TBL] [Abstract][Full Text] [Related]
18. Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells.
Liu F; Bu Z; Zhao F; Xiao D
Cancer Sci; 2018 Jan; 109(1):65-73. PubMed ID: 29059496
[TBL] [Abstract][Full Text] [Related]
19. Interluekin-17A (IL17A).
Chen K; Kolls JK
Gene; 2017 May; 614():8-14. PubMed ID: 28122268
[TBL] [Abstract][Full Text] [Related]
20. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
